(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

British pharmaceutical giant AstraZeneca on Monday announced an agreement to buy Belgian cell therapy firm EsoBiotec for up ...

CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...